Immune thrombocytopenia in adults: an update.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22949345.
- Also identified by DOI 10.3949/ccjm.79a.11027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune thrombocytopenia (ITP) in adults is a chronic disease resulting from increased platelet destruction and impaired platelet production. Splenectomy remains the most effective and durable treatment in cases that are refractory to first-line therapy, but its use has declined because of the availability of alternate medical therapy, the associated risk of infection, and concern for surgery-related complications. Rituximab (Rituxan) may be an effective alternative but carries the risk of immunosuppression.
Medical subject headings
- Purpura, Thrombocytopenic, Idiopathic